Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.32 and traded as high as $3.89. Cumberland Pharmaceuticals shares last traded at $3.74, with a volume of 85,503 shares changing hands.

Analysts Set New Price Targets

CPIX has been the topic of several research analyst reports. Wall Street Zen upgraded Cumberland Pharmaceuticals to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The company has a 50 day moving average of $3.54 and a 200 day moving average of $3.32. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23. The stock has a market capitalization of $55.95 million, a price-to-earnings ratio of -15.58 and a beta of -0.53.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 8.06% and a positive return on equity of 5.13%. The company had revenue of $8.29 million during the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Cumberland Pharmaceuticals during the second quarter worth $34,000. Heron Bay Capital Management purchased a new stake in Cumberland Pharmaceuticals during the 2nd quarter worth about $111,000. Two Sigma Investments LP boosted its position in shares of Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after acquiring an additional 5,326 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after acquiring an additional 4,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after acquiring an additional 27,980 shares in the last quarter. 15.51% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.